MX2021003660A - Composicion inyectable. - Google Patents
Composicion inyectable.Info
- Publication number
- MX2021003660A MX2021003660A MX2021003660A MX2021003660A MX2021003660A MX 2021003660 A MX2021003660 A MX 2021003660A MX 2021003660 A MX2021003660 A MX 2021003660A MX 2021003660 A MX2021003660 A MX 2021003660A MX 2021003660 A MX2021003660 A MX 2021003660A
- Authority
- MX
- Mexico
- Prior art keywords
- injectable composition
- cancer
- lymphocytes
- protein
- activity
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102000040856 WT1 Human genes 0.000 abstract 1
- 108700020467 WT1 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Abstract
La presente invención se refiere a una preparación liofilizada que comprende dos o más péptidos del antígeno de cáncer derivados de la proteína WT1 con actividad para la inducción de linfocitos T citotóxicos para la terapia de vacuna de péptidos contra el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018185532 | 2018-09-28 | ||
PCT/JP2019/038223 WO2020067453A1 (ja) | 2018-09-28 | 2019-09-27 | 注射用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003660A true MX2021003660A (es) | 2021-05-28 |
Family
ID=69951879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003660A MX2021003660A (es) | 2018-09-28 | 2019-09-27 | Composicion inyectable. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210338587A1 (es) |
EP (1) | EP3858377A4 (es) |
JP (1) | JP7162675B2 (es) |
KR (1) | KR20210068060A (es) |
CN (1) | CN113382746A (es) |
AU (1) | AU2019349329A1 (es) |
CA (1) | CA3113212A1 (es) |
MX (1) | MX2021003660A (es) |
WO (1) | WO2020067453A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023013755A1 (ja) * | 2021-08-06 | 2023-02-09 | ブライトパス・バイオ株式会社 | がんペプチドワクチンカクテル製剤、及びその製造方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI9912663B8 (pt) | 1998-07-31 | 2021-07-06 | Int Inst Cancer Immunology Inc | vacina contra cáncer e polipeptìdeo. |
DE69938970D1 (de) | 1998-09-30 | 2008-08-07 | Corixa Corp | Zusammensetzungen und verfahren für wt1-spezifische immunotherapie |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Hla−a24発現トランスジェニック動物及びその利用 |
KR100863853B1 (ko) | 2001-03-22 | 2008-10-15 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 더블유티1 개변 펩티드 |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
CN100408683C (zh) | 2002-06-12 | 2008-08-06 | 株式会社国际癌症免疫研究所 | Hla-a24限制性癌抗原肽 |
WO2004026897A1 (ja) | 2002-09-20 | 2004-04-01 | Chugai Seiyaku Kabushiki Kaisha | Wt1置換型ペプチド |
US7353321B2 (en) | 2003-01-13 | 2008-04-01 | Sierra Logic | Integrated-circuit implementation of a storage-shelf router and a path controller card for combined use in high-availability mass-storage-device shelves that may be incorporated within disk arrays |
KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 유래의 hla-dr 결합성 항원 펩티드 |
CA2548135C (en) | 2003-12-01 | 2014-04-22 | Sloan-Kettering Institute For Cancer Research | Synthetic hla binding peptide analogues and uses thereof |
ES2507097T3 (es) | 2005-01-19 | 2014-10-14 | Sumitomo Dainippon Pharma Co., Ltd. | Composición emulsionada para dilución y composición de vacuna contra el cáncer |
EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
DE602006017880D1 (es) | 2005-11-30 | 2010-12-09 | Chugai Pharmaceutical Co Ltd | |
PL2010209T3 (pl) | 2006-04-10 | 2017-04-28 | Sloan Kettering Inst For Cancer Res | Immunogeniczne peptydy WT-1 i sposoby ich użycia |
WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
NZ712148A (en) | 2013-03-29 | 2019-11-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1 antigen peptide conjugate vaccine |
CA2962630C (en) * | 2014-09-27 | 2023-02-21 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition for injection |
CN107921106B (zh) | 2015-05-20 | 2023-09-08 | 住友制药株式会社 | Wt1抗原肽和免疫调节剂的组合用途 |
WO2018101309A1 (ja) | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
-
2019
- 2019-09-27 CN CN201980077600.9A patent/CN113382746A/zh active Pending
- 2019-09-27 JP JP2020549451A patent/JP7162675B2/ja active Active
- 2019-09-27 AU AU2019349329A patent/AU2019349329A1/en active Pending
- 2019-09-27 EP EP19864323.1A patent/EP3858377A4/en active Pending
- 2019-09-27 US US17/279,807 patent/US20210338587A1/en active Pending
- 2019-09-27 MX MX2021003660A patent/MX2021003660A/es unknown
- 2019-09-27 KR KR1020217011972A patent/KR20210068060A/ko active Search and Examination
- 2019-09-27 CA CA3113212A patent/CA3113212A1/en active Pending
- 2019-09-27 WO PCT/JP2019/038223 patent/WO2020067453A1/ja unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020067453A1 (ja) | 2020-04-02 |
JP7162675B2 (ja) | 2022-10-28 |
JPWO2020067453A1 (ja) | 2021-09-09 |
KR20210068060A (ko) | 2021-06-08 |
AU2019349329A1 (en) | 2021-04-29 |
EP3858377A1 (en) | 2021-08-04 |
CA3113212A1 (en) | 2020-04-02 |
EP3858377A4 (en) | 2022-11-30 |
CN113382746A (zh) | 2021-09-10 |
US20210338587A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
EA201791925A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
MX2019005272A (es) | Peptidos cancerigenos universales derivados de telomerasa. | |
EA201792632A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
NZ734197A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
EA201791853A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака | |
NZ712148A (en) | Wt1 antigen peptide conjugate vaccine | |
NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
PH12020500579A1 (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
MX2016002937A (es) | Vacuna oncologica. | |
MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
AR095386A1 (es) | Péptidos de kntc2 y vacunas que los contienen | |
BR112017023479A2 (pt) | composições peptídicas e métodos de uso | |
ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
MX2021003660A (es) | Composicion inyectable. | |
RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
BR112017002206A2 (pt) | peptídeo derivado de koc1 e vacina incluindo o mesmo | |
EP3868778A3 (en) | Cdc45l peptides and vaccines including the same | |
MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
WO2015149016A3 (en) | Breast and ovarian cancer vaccines | |
IL291127A (en) | Amino-end extension sequence for expression of recombinant medicinal peptides |